AcelRx Pharmaceuticals, Inc. (ACRX)

AcelRx Pharmaceuticals, Inc. (ACRX) Healthcare & Pipeline Overview

AcelRx Pharmaceuticals, Inc. develops and commercializes acute pain therapies, with DSUVIA as its lead product, targeting moderate-to-severe pain. Facing a competitive landscape in the specialty pharmaceutical sector, AcelRx focuses on sublingual tablet formulations and patient-controlled analgesia systems.

What Is the Investment Thesis for ACRX?

AcelRx Pharmaceuticals, Inc. presents a high-risk, high-reward investment opportunity within the specialty pharmaceutical sector. The company's focus on acute pain management, particularly with its lead product DSUVIA, addresses a significant market need. However, AcelRx's negative profit margin of -51035.7% and gross margin of -4075.0% indicate substantial financial challenges. Successful commercialization of DSUVIA and advancement of its pipeline products, such as ZALVISO and ARX-02, are critical catalysts. The company's beta of 0.52 suggests lower volatility compared to the market. Investors should closely monitor AcelRx's ability to secure regulatory approvals, manage its cash burn, and achieve sustainable revenue growth. The potential for LTX-608 to address COVID-19-related complications adds a speculative element to the investment thesis.

Based on FMP financials and quantitative analysis

ACRX Key Highlights

• Market Cap of $14.58M reflects its small size and potential for high volatility.
• Profit Margin of -51035.7% indicates significant losses and operational challenges.
• Gross Margin of -4075.0% highlights the high cost of goods sold relative to revenue.
• Beta of 0.52 suggests lower volatility compared to the overall market.
• Focus on acute pain management with DSUVIA as its lead product.

Who Are ACRX's Competitors?

ACRX is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are ACRX's Key Strengths?

• Innovative drug delivery systems (sublingual tablets, PCA systems).
• Focus on addressing unmet needs in acute pain management.
• Pipeline of product candidates targeting various pain conditions.
• DSUVIA approval provides a commercial foundation.

What Are ACRX's Weaknesses?

• Significant financial losses and negative profit margins.
• Limited commercial infrastructure and resources.
• Dependence on successful commercialization of DSUVIA.
• Regulatory and clinical trial risks associated with drug development.

What Could Drive ACRX Stock Higher?

• Potential FDA approval and launch of ZALVISO, the patient-controlled analgesia system, could significantly boost revenue.
• Continued commercial expansion of DSUVIA into new hospital systems and ambulatory surgical centers.
• Progress in clinical trials for ARX-02, targeting cancer breakthrough pain, could lead to positive data releases.
• Research and development efforts for LTX-608 as a potential antiviral treatment.

What Are the Key Risks for ACRX?

• Financial-distress signal — its Altman Z-Score of -22.16 sits in the distress zone (elevated bankruptcy risk).
• Negative return on equity (-93.0%) — the business is not currently generating profit on shareholder capital.
• Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
• AcelRx's significant financial losses and negative profit margins raise concerns about its long-term sustainability.
• Regulatory setbacks or delays in the approval of ZALVISO could negatively impact the company's growth prospects.
• Competition from established pharmaceutical companies and generic erosion of DSUVIA could limit market share.
• Product liability claims related to DSUVIA or other products could result in significant financial liabilities.
• Dependence on a limited number of products increases the vulnerability to market fluctuations and competitive pressures.

What Are the Growth Opportunities for ACRX?

• DSUVIA Commercial Expansion: Expanding the commercial reach of DSUVIA represents a significant growth opportunity for AcelRx. Targeting specific patient populations, such as post-operative patients and those in emergency room settings, can drive increased adoption. The market for acute pain management is substantial, with a global value estimated at billions of dollars. Successful penetration into key hospital systems and ambulatory surgical centers is crucial for realizing this growth potential. Timeline: Ongoing.
• ZALVISO Regulatory Approval and Launch: Securing regulatory approval and launching ZALVISO, its patient-controlled analgesia system, offers another avenue for growth. ZALVISO's unique design allows patients to self-administer pain medication, potentially reducing the burden on healthcare providers. The market for PCA systems is growing, driven by the demand for personalized pain management solutions. Successful commercialization of ZALVISO could significantly contribute to AcelRx's revenue. Timeline: Dependent on regulatory approval.
• ARX-02 Clinical Development: Advancing the clinical development of ARX-02 for cancer breakthrough pain in opioid-tolerant patients presents a targeted growth opportunity. Addressing the unmet needs of this patient population could lead to a valuable niche market. The prevalence of cancer pain and the limitations of existing treatments create a demand for novel analgesics. Positive clinical trial results and subsequent regulatory approval are essential for realizing this potential. Timeline: Ongoing clinical trials.
• LTX-608 Antiviral Application: Exploring the antiviral application of LTX-608, particularly in the context of COVID-19 and related complications, offers a speculative but potentially high-impact growth opportunity. If LTX-608 demonstrates efficacy in treating ARDS, DIC, or acute pancreatitis associated with viral infections, it could address a significant unmet medical need. The market for antiviral therapies remains substantial, driven by emerging infectious diseases. Timeline: Ongoing research and development.
• Strategic Partnerships and Acquisitions: Pursuing strategic partnerships and acquisitions could accelerate AcelRx's growth trajectory. Collaborating with larger pharmaceutical companies or acquiring complementary technologies could expand its product portfolio and market reach. The pharmaceutical industry is characterized by frequent mergers and acquisitions, and AcelRx could benefit from such strategic moves. Timeline: Ongoing.

What Opportunities Does ACRX Have?

• Expanding the market reach of DSUVIA.
• Securing regulatory approval and launching ZALVISO.
• Advancing clinical development of ARX-02 and ARX-03.
• Exploring new applications for LTX-608.
• Strategic partnerships and acquisitions.

What Threats Does ACRX Face?

• Competition from established pharmaceutical companies.
• Generic erosion of existing products.
• Unfavorable regulatory decisions.
• Product liability claims.
• Changes in healthcare reimbursement policies.

What Are ACRX's Competitive Advantages?

• Proprietary drug formulations and delivery systems.
• Patent protection for key products and technologies.
• Established relationships with healthcare providers.
• Specialized expertise in acute pain management.

What Does ACRX Do?

AcelRx Pharmaceuticals, Inc., founded in 2005 and based in Hayward, California, is a specialty pharmaceutical company dedicated to the development and commercialization of innovative therapies for the treatment of acute pain. Originally named SuRx, Inc., the company rebranded to AcelRx Pharmaceuticals, Inc. in August 2006. The company's primary focus is on addressing unmet needs in pain management through advanced drug delivery systems. AcelRx's lead product candidate is DSUVIA and DZUVEO, a 30 mcg sufentanil sublingual tablet designed for the treatment of moderate-to-severe acute pain. This product aims to provide a non-invasive and rapidly acting pain relief option. In addition to DSUVIA, AcelRx is developing ZALVISO, a pre-programmed, patient-controlled analgesia (PCA) system. ZALVISO allows hospital patients experiencing moderate-to-severe acute pain to self-administer sufentanil sublingual tablets, providing a tailored approach to pain management. The company is also advancing ARX-02, currently in Phase 2 clinical trials, targeting cancer breakthrough pain in opioid-tolerant patients. Furthermore, AcelRx is exploring ARX-03 for mild sedation and pain relief during painful procedures. AcelRx's pipeline includes Niyad, a regional anticoagulant intended for use in extracorporeal circuits, and LTX-608, a nafamostat formulation for direct IV infusion, investigated as a potential antiviral treatment for COVID-19, acute respiratory distress syndrome (ARDS), disseminated intravascular coagulation (DIC), and acute pancreatitis. AcelRx aims to improve patient outcomes by offering innovative and convenient pain management solutions.

What Products and Services Does ACRX Offer?

• Develop and commercialize therapies for acute pain management.
• Offer DSUVIA, a sublingual tablet for moderate-to-severe acute pain.
• Develop ZALVISO, a patient-controlled analgesia system.
• Advance ARX-02 for cancer breakthrough pain in opioid-tolerant patients.
• Explore ARX-03 for mild sedation and pain relief during painful procedures.
• Investigate LTX-608 as a potential antiviral treatment.

How Does ACRX Make Money?

• Develop proprietary pharmaceutical products for acute pain management.
• Seek regulatory approval for its drug candidates from agencies like the FDA.
• Commercialize approved products through direct sales and marketing efforts.
• Potentially license or partner with other companies for product distribution.

What Industry Does ACRX Operate In?

AcelRx Pharmaceuticals, Inc. operates within the specialty pharmaceutical industry, which is characterized by intense competition and stringent regulatory requirements. The acute pain management market is driven by factors such as an aging population, increasing surgical procedures, and the need for effective pain relief options. Key trends include the development of non-opioid analgesics and advanced drug delivery systems. AcelRx's focus on sublingual formulations and patient-controlled analgesia positions it within the innovative segment of the market. The company faces competition from established pharmaceutical companies and emerging biotech firms.

Who Are ACRX's Key Customers?

• Hospitals and acute care facilities.
• Ambulatory surgical centers.
• Emergency rooms.
• Patients experiencing moderate-to-severe acute pain.

Company Profile

AcelRx Pharmaceuticals, Inc. operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. It is headquartered in Hayward, US. The company is led by CEO Vincent J. Angotti. ACRX has traded publicly since 2011.

F-Score 3/9Financial Health

AcelRx Pharmaceuticals, Inc.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -22.16 places it in the distress zone, a signal of elevated financial risk.

ROE -93%Key Financial Metrics

Return on equity for AcelRx Pharmaceuticals, Inc. stands at -93.0%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -47.3%, showing how much profit it generates from its asset base. Its free cash flow yield is -67.5%, a gauge of the cash the business throws off relative to its market value. A current ratio of 5.30 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -41.2%, the inverse of the P/E and a quick read on earnings relative to price.

ACRX Valuation & Market Position

With a $14.58M market cap, AcelRx Pharmaceuticals, Inc. sits in the micro-cap segment of the market. Relative to its peer group, ACRX's quantitative score of 43/100 is below the peer average of 66/100.

ACRX Financials

ACRX Latest News

ACRX Analyst Consensus

ACRX MoonshotScore

ACRX Healthcare Stock FAQ

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources